Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy.
about
Peripheral artery disease: current insight into the disease and its diagnosis and management.Outcomes for clinical studies assessing drug and revascularization therapies for claudication and critical limb ischemia in peripheral artery diseaseAssessment of functional status and quality of life in claudication.Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies.Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study.
P2860
Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Randomized trial of AT-1015 fo ...... with no evidence of efficacy.
@en
Randomized trial of AT-1015 fo ...... with no evidence of efficacy.
@nl
type
label
Randomized trial of AT-1015 fo ...... with no evidence of efficacy.
@en
Randomized trial of AT-1015 fo ...... with no evidence of efficacy.
@nl
prefLabel
Randomized trial of AT-1015 fo ...... with no evidence of efficacy.
@en
Randomized trial of AT-1015 fo ...... with no evidence of efficacy.
@nl
P2093
P2860
P1433
P1476
Randomized trial of AT-1015 fo ...... with no evidence of efficacy.
@en
P2093
Alan T Hirsch
D Craig Brater
Jeffrey W Olin
Mark A Creager
William R Hiatt
P2860
P356
10.1191/1358863X04VM520OA
P577
2004-02-01T00:00:00Z